AAAAAA

   
Results: 1-25 | 26-37
Results: 1-25/37
Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors
Authors: Le Moing, V Chene, G Carrieri, MP Besnier, JM Masquelier, B Salamon, R Bazin, C Moatti, JP Raffi, F Leport, C
Citation: V. Le Moing et al., Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors, J ACQ IMM D, 27(4), 2001, pp. 372-376
Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy - Standardization to the general population
Authors: Lewden, C Raffi, F Chene, G Sobel, A Leport, C
Citation: C. Lewden et al., Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy - Standardization to the general population, J ACQ IMM D, 26(5), 2001, pp. 480-482
Definite Streptococcus bovis endocarditis: characteristics in 20 patients
Authors: Duval, X Papastamopoulos, V Longuet, P Benoit, C Perronne, C Leport, C Vilde, JL
Citation: X. Duval et al., Definite Streptococcus bovis endocarditis: characteristics in 20 patients, CL MICRO IN, 7(1), 2001, pp. 3-10
Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus
Authors: Leport, C Franck, J Chene, G Derouin, F Ecobichon, JL Pueyo, S Miro, JM Luft, BJ Morlat, P Dumon, H
Citation: C. Leport et al., Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus, CL DIAG LAB, 8(3), 2001, pp. 579-584
Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patients
Authors: Fidouh-Houhou, N Duval, X Bissuel, F Bourbonneux, V Flandre, P Ecobichon, JL Jordn, MC Vilde, JL Brun-Vezinet, F Leport, C
Citation: N. Fidouh-houhou et al., Salivary cytomegalovirus (CMV) shedding, glycoprotein B genotype distribution, and CMV disease in human immunodeficiency virus-seropositive patients, CLIN INF D, 33(8), 2001, pp. 1406-1411
Venous access port-related bacteremia in patients with acquired immunodeficiency syndrome or cancer: The reservoir as a diagnostic and therapeutic tool
Authors: Longuet, P Douard, MC Arlet, G Molina, JM Benoit, C Leport, C
Citation: P. Longuet et al., Venous access port-related bacteremia in patients with acquired immunodeficiency syndrome or cancer: The reservoir as a diagnostic and therapeutic tool, CLIN INF D, 32(12), 2001, pp. 1776-1783
Paradoxical aggravation of tuberculosis after antiretroviral treatment in HIV-infected patients
Authors: Duval, X Trad, S Le Moing, V Longuet, P Leport, C Vilde, JL
Citation: X. Duval et al., Paradoxical aggravation of tuberculosis after antiretroviral treatment in HIV-infected patients, PRESSE MED, 30(5), 2001, pp. 213-216
Patient information: guidelines for physicians
Authors: Bail, P Bizel, P Bonnard, J Compagnon, C Dosquet, P Dubois, S Dupuis, G Fabre, H Glorion, B Lienhart, A Nicolas, F Noel, AP Pazart, L Pinell, P Pellerin, D Sargos, P Serin, D Thouvenin, D Thurin, JM Chapiro, O Cordonnier, D Darcourt, G Delcey, M Esper, C Freile, R Grall, JC Haxaire, C Herrmann, P Hirsch, E Hirszowski, F Jacquet, JP Lascoumes, P Lassner, E Leport, C Lieutaud, P Locquet, C Mairesse, JP Mayaud, C May-Levin, F Michel, C Mopin, J Moser, S Papa, M Perrier, JM Pochet, P Richard, D Sautron, JB Torre, E Tricoire, MJ Vasseur, E Wagner-Ballon, J
Citation: P. Bail et al., Patient information: guidelines for physicians, J MAL VASC, 26(2), 2001, pp. 101-104
Galactorrhoea, hyperprolactinaemia, and protease inhibitors
Authors: Duval, X Larger, E Longuet, P Leport, C Vilde, JL
Citation: X. Duval et al., Galactorrhoea, hyperprolactinaemia, and protease inhibitors, LANCET, 357(9254), 2001, pp. 475-475
Adverse reactions to cotrimoxazole in HIV-infected patients: Predictive factors and subsequent HIV disease progression
Authors: Rabaud, C Charreau, I Izard, S Raffi, F Meiffredy, V Leport, C Guillemin, F Yeni, P Aboulker, JP
Citation: C. Rabaud et al., Adverse reactions to cotrimoxazole in HIV-infected patients: Predictive factors and subsequent HIV disease progression, SC J IN DIS, 33(10), 2001, pp. 759-764
Topical cidofovir for bowenoid papulosis in an HIV-infected patient
Authors: Descamps, V Duval, X Grossin, M Crickx, B Leport, C
Citation: V. Descamps et al., Topical cidofovir for bowenoid papulosis in an HIV-infected patient, BR J DERM, 144(3), 2001, pp. 642-643
Long-term immunologic response in HIV-infected patients with CD4 cell counts <= 50/mm(3) when initiating protease inhibitor therapy.
Authors: Le Moing, V Eid, Z Ecobichon, JL Duval, X Longuet, P Elbim, C Brun-Vezinet, F Leport, C Vilde, JL
Citation: V. Le Moing et al., Long-term immunologic response in HIV-infected patients with CD4 cell counts <= 50/mm(3) when initiating protease inhibitor therapy., ANN MED IN, 152(1), 2001, pp. 11-14
Recurrent Staphylococcus aureus extracerebral infections complicating hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber disease)
Authors: Duval, X Djendli, S Le Moing, V Longuet, P Barry, B Leport, C Vilde, JL
Citation: X. Duval et al., Recurrent Staphylococcus aureus extracerebral infections complicating hereditary hemorrhagic telangiectasia (Osler-Rendu-Weber disease), AM J MED, 110(8), 2001, pp. 671-672
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
Authors: Masur, H Kaplan, JE Holmes, KK Alston, BL Ampel, N Anderson, JR Baker, AC Barr, D Bartlett, JG Bennett, JE Benson, CA Bozzette, SA Chaisson, RE Crumpacker, CS Currier, JS Deyton, L Drew, WL Duncan, WR Eisinger, RW El-Sadr, W Feinberg, J Freedberg, KA Furrer, H Gnann, JW Goldberger, MJ Goldie, S Goosby, EP Gross, PA Hafner, R Havlir, D Hooton, TM Jabs, DA Jacobson, MA Janoff, E Kitahata, M Kovacs, JV Leport, C Levin, MJ Lopez, JC Marco, M Mayers, DL Melnick, DA Mofenson, LM Montaner, JSG Moore, R Neaton, J Nelson, C O'Neill, JF Palefsky, J Pau, A Phair, JP Piscitelli, S Polis, MA Quinn, TC Reiss, P Rimland, D Sears, CL Seeff, L Sepkowitz, KA Slama, TG Sloand, EM Spector, SA Thomas, DL Van Dyke, RB Watts, DH Wheat, LJ Whitcup, SM Williams, P Wright, TC Castro, KG DeCock, KM Dowell, SF Dworkin, MS Dykewicz, C Ellerbrock, T Hajjeh, R Holmberg, S Holtgrave, DR Jaffe, HW Jones, JL Juranek, DD Mast, E Navin, T Pellett, PE Reeves, WC Stewart, JA Villarino, ME
Citation: H. Masur et al., 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, CLIN INF D, 30, 2000, pp. S29-S65
Modalities of palliative care in hospitalized patients with advanced AIDS
Authors: Vincent, I D'Herouville, D Moulin, P Bugler, C Fraval, J Mallet, D Salamagne, MH Vilde, JL Jodelet, D Leport, C
Citation: I. Vincent et al., Modalities of palliative care in hospitalized patients with advanced AIDS, AIDS CARE, 12(2), 2000, pp. 211-219
Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy
Authors: Salmon-Ceron, D Mazeron, MC Chaput, S Boukli, N Senechal, R Houhou, N Katlama, C Matheron, S Fillet, AM Gozlan, J Leport, C Jeantils, V Freymuth, F Costagliola, D
Citation: D. Salmon-ceron et al., Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy, AIDS, 14(8), 2000, pp. 1041-1049
Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients
Authors: Anduze-Faris, BM Fillet, AM Gozlan, J Lancar, R Boukli, N Gasnault, J Caumes, E Livartowsky, J Matheron, S Leport, C Salmon, D Costagliola, D Katlama, C
Citation: Bm. Anduze-faris et al., Induction and maintenance therapy of cytomegalovirus central nervous system infection in HIV-infected patients, AIDS, 14(5), 2000, pp. 517-524
Cotrimoxazole for prenatal treatment of congenital toxoplasmosis?
Authors: Derouin, F Jacqz-Aigrain, E Thulliez, P Couvreur, J Leport, C
Citation: F. Derouin et al., Cotrimoxazole for prenatal treatment of congenital toxoplasmosis?, PARASIT TOD, 16(6), 2000, pp. 254-256
Efavirenz induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir
Authors: Duval, X Le Moing, V Longuet, P Leport, C Vilde, JL Lamotte, C Peytavin, G Farinotti, R
Citation: X. Duval et al., Efavirenz induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir, ANTIM AG CH, 44(9), 2000, pp. 2593-2593
Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients
Authors: Saves, M Raffi, F Clevenbergh, P Marchou, B Waldner-Combernoux, A Morlat, P Le Moing, V Riviere, C Chene, G Leport, C
Citation: M. Saves et al., Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients, ANTIM AG CH, 44(12), 2000, pp. 3451-3455
High levels of IL-10 and determination of other cytokines and chemokines in HIV-associated haemophagocytic syndrome
Authors: Benveniste, O Dereuddre-Bosquet, N Clayette, P Leport, C Vilde, JL Dormont, D
Citation: O. Benveniste et al., High levels of IL-10 and determination of other cytokines and chemokines in HIV-associated haemophagocytic syndrome, CLIN EXP IM, 121(2), 2000, pp. 320-323
Clinical outcome of patients with HIV-1 infection according to immunologicand virologic response after 6 months of highly active antiretroviral therapy
Authors: Grabar, S Le Moing, V Goujard, C Leport, C Kazatchkine, MD Costagliola, D Weiss, L
Citation: S. Grabar et al., Clinical outcome of patients with HIV-1 infection according to immunologicand virologic response after 6 months of highly active antiretroviral therapy, ANN INT MED, 133(6), 2000, pp. 401-410
Lipodystrophy: a complication of protease inhibitors in HIV seropositive patients.
Authors: Hermieu, JF Leport, C Ravery, V Delmas, V Boccon-Gibod, L
Citation: Jf. Hermieu et al., Lipodystrophy: a complication of protease inhibitors in HIV seropositive patients., PROG UROL, 9(3), 1999, pp. 537-540
Use of corticosteroids in glomerulonephritis related to infective endocarditis: Three cases and review
Authors: Le Moing, V Lacassin, F Delahousse, M Duval, X Longuet, P Leport, C Vilde, JL
Citation: V. Le Moing et al., Use of corticosteroids in glomerulonephritis related to infective endocarditis: Three cases and review, CLIN INF D, 28(5), 1999, pp. 1057-1061
Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir
Authors: Benveniste, O Longuet, P Duval, X Le Moing, V Leport, C Vilde, JL
Citation: O. Benveniste et al., Two episodes of acute renal failure, rhabdomyolysis, and severe hepatitis in an AIDS patient successively treated with ritonavir and indinavir, CLIN INF D, 28(5), 1999, pp. 1180-1181
Risultati: 1-25 | 26-37